both in modulating endothelial cell MMP production and localization (Brooks et al., 1996; Sugiura and Berditchevski, 1999). However, to date no direct interaction between members of the TIMP family and integrins has been demonstrated.
The goals of the current study are to (1) demonstrate that TIMP-2 inhibition of human microvascular endothelial cell (hMVEC) proliferation both in vitro and in vivo can be dissociated from MMP inhibitory activity; (2) define the cell surface receptor that mediates these inhibitory effects of TIMP-2 on endothelial cell proliferation; and (3) describe the mechanism of TIMP-2 inhibition of growth factor stimulation. To accomplish these goals, we utilize recombinant TIMP-2 and a mutant form of TIMP-2, referred to as AlaϩTIMP-2, which contains a single alanine residue appended to the amino-terminal cysteine of the wild-type TIMP-2 which results in loss of MMP inhibitor activity (Hoegy et Figure 3E ). In contrast, GD25-␤1A cells pretreated with TIMP-2, prior to PDGF stimulation, show a significant decrease of 50%-60% in cognate receptor phosphorylation ( Figure 4B ). This effect of TIMP-2 on significant reduction in proliferation to levels statistically indistinguishable from that observed in unstimulated FGFR-1 and KDR phosphorylation is dose dependent. In TIMP-2-treated hMVECs orthovanadate completely cells ( Figure 3E ). These data with the GD25-␤1A cells are similar to those observed following TIMP-2 pretreatment restores RTK phosphorylation to levels comparable 
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hMVECs. Statistical significance is indicated (** p Ͻ 0.01). (B) Dose-dependent suppression of FGF-2-or VEGF-A-induced hMVEC proliferation. ᭺-TIMP-2ϩFGF-2; ᮀ-TIMP-2ϩVEGF-A;
TIMP-2 Suppresses hMVEC Proliferation In Vitro
